Novo Holdings Participates in €90 Million Series A Financing Round for Orbis Medicines to Support Development of Oral Macrocycle Drugs
- Financing to support the development of Orbis’ pipeline of next-generation macrocycles, nCycles, with an initial focus on validated blockbuster biologic targets
- Orbis’ nGen platform systematically explores oral macrocycle design with automated chemistry and machine learning
- Novo Holdings Partner, Morten Graugaard, to lead Orbis as CEO
COPENHAGEN – January 6, 2025 – Novo Holdings today announced its participation in a €90 million Series A financing for Orbis Medicines. The round was led by New Enterprise Associates (NEA), with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark, alongside existing investors Novo Holdings and Forbion. Morten Graugaard, Partner at Novo Holdings, has been appointed the Chief Executive Officer of Orbis Medicines following nearly three years serving as Executive Chair of its Board of Directors.
